Numerous studies have confirmed that DCN can exert inhibitory effects in various solid tumors, particularly in oral squamous cell carcinoma (OSCC), by activating its downstream pathways through binding with the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) receptor, or by stabilizing and enhancing the expression of the tumor suppressor gene p53 to mediate apoptosis in cancer cells that have undergone mutation. This evidence concerns the gene EGFR and cancer.